Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNPR NASDAQ:MSTR NASDAQ:SEZL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$65.04+0.9%$57.70$28.40▼$105.00$431.62M1.49185,409 shs119,419 shsMSTRStrategy$159.09+4.9%$154.16$104.17▼$457.22$53.14B3.5914.14 million shs19.15 million shsSEZLSezzle$118.15-0.7%$83.39$49.50▼$186.74$4.00B6.91737,809 shs544,597 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics+0.95%+3.04%+29.77%+18.66%+100.37%MSTRStrategy+4.91%-0.50%+0.57%+22.85%-56.32%SEZLSezzle-0.71%+14.93%+54.36%+61.96%+6.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$65.04+0.9%$57.70$28.40▼$105.00$431.62M1.49185,409 shs119,419 shsMSTRStrategy$159.09+4.9%$154.16$104.17▼$457.22$53.14B3.5914.14 million shs19.15 million shsSEZLSezzle$118.15-0.7%$83.39$49.50▼$186.74$4.00B6.91737,809 shs544,597 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics+0.95%+3.04%+29.77%+18.66%+100.37%MSTRStrategy+4.91%-0.50%+0.57%+22.85%-56.32%SEZLSezzle-0.71%+14.93%+54.36%+61.96%+6.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNPRMonopar Therapeutics 3.00Buy$107.0064.51% UpsideMSTRStrategy 2.75Moderate Buy$322.21102.54% UpsideSEZLSezzle 2.86Moderate Buy$118.00-0.13% DownsideCurrent Analyst Ratings BreakdownLatest MNPR, MSTR, and SEZL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026SEZLSezzle Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/19/2026MSTRStrategy TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$395.00 ➝ $400.005/18/2026MSTRStrategy Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026MSTRStrategy Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/7/2026SEZLSezzle Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C+)5/7/2026MSTRStrategy TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$385.00 ➝ $395.005/7/2026SEZLSezzle TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/7/2026MSTRStrategy Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$185.00 ➝ $224.005/7/2026MSTRStrategy B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$200.00 ➝ $215.005/7/2026SEZLSezzle Keefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$85.00 ➝ $115.005/7/2026SEZLSezzle Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$94.00 ➝ $122.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNPRMonopar TherapeuticsN/AN/AN/AN/A$20.21 per shareN/AMSTRStrategy$477.23M116.83N/AN/A$104.58 per share1.52SEZLSezzle$480.91M8.26$3.79 per share31.19$5.85 per share20.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)MSTRStrategy-$3.85B-$40.16N/A2.13N/A-2,482.01%-26.97%-19.15%7/30/2026 (Estimated)SEZLSezzle$133.13M$4.2128.0618.75N/A30.83%87.46%36.29%8/6/2026 (Estimated)Latest MNPR, MSTR, and SEZL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/6/2026Q1 2026SEZLSezzle$1.24$1.43+$0.19$1.47$127.74 million$135.54 million5/5/2026Q1 2026MSTRStrategy-$0.8620-$38.25-$37.3880-$38.25$120.75 million$124.30 million3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AMSTRStrategyN/AN/AN/AN/AN/ASEZLSezzleN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNPRMonopar TherapeuticsN/A56.0456.04MSTRStrategy0.226.056.05SEZLSezzle0.733.653.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNPRMonopar Therapeutics1.83%MSTRStrategy59.84%SEZLSezzle2.02%Insider OwnershipCompanyInsider OwnershipMNPRMonopar Therapeutics20.50%MSTRStrategy6.49%SEZLSezzle49.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableMSTRStrategy1,539350.45 million327.70 millionOptionableSEZLSezzle54033.63 million16.99 millionNot OptionableMNPR, MSTR, and SEZL HeadlinesRecent News About These CompaniesSezzle (NASDAQ:SEZL) SVP Sells $374,114.16 in StockMay 29 at 5:05 PM | marketbeat.comWhy Sezzle (SEZL) Is Up 10.6% After Raising 2026 Outlook And Highlighting Insider AlignmentMay 29 at 12:13 PM | finance.yahoo.comSezzle (NASDAQ:SEZL) Upgraded to Strong-Buy at Zacks ResearchMay 29 at 6:38 AM | marketbeat.comSezzle is the best performing financial stock in the past monthMay 29 at 1:37 AM | msn.comSezzle Inc (SEZL) Shares Surge 5.5% -- What GF Score of 67 Tells InvestorsMay 27 at 11:01 PM | gurufocus.comIs Sezzle Inc. (SEZL) a Solid Growth Stock? 3 Reasons to Think "Yes"May 25, 2026 | zacks.comDAVE vs. SEZL: Which Fintech Stock Is the Better Buy Now?May 25, 2026 | zacks.comSezzle Inc. (NASDAQ:SEZL) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 23, 2026 | marketbeat.comSezzle Inc. (NASDAQ: SEZL) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.May 22, 2026 | financialpost.comFSezzle Inc. (NASDAQ: SEZL) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.May 22, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sezzle Inc. - SEZLMay 21, 2026 | prnewswire.comGlancy Prongay Wolke & Rotter LLP Announces Investigation of Sezzle Inc. (SEZL) on Behalf of InvestorsMay 20, 2026 | businesswire.comSEZL Investors Have Opportunity to Join Sezzle Inc. Fraud Investigation with the Schall Law FirmMay 19, 2026 | globenewswire.comSEZZLE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sezzle, Inc. on Behalf of Sezzle Stockholders and Encourages Investors to Contact the FirmMay 19, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sezzle Inc. - SEZLMay 19, 2026 | globenewswire.comLaw Offices of Howard G. Smith Announces Investigation of Sezzle Inc. (SEZL) on Behalf of InvestorsMay 19, 2026 | businesswire.comSezzle Inc. $SEZL Shares Purchased by UBS Group AGMay 19, 2026 | marketbeat.comThe Law Offices of Frank R. Cruz Announces Investigation of Sezzle Inc. (SEZL) on Behalf of InvestorsMay 18, 2026 | businesswire.comAccredited Investors Inc. Invests $57.96 Million in Sezzle Inc. $SEZLMay 17, 2026 | marketbeat.comSezzle And Pagaya Partner Up To Expand BNPL OperationsMay 16, 2026 | seekingalpha.comAs yields climb, these interest-rate sensitive stocks rank best on Seeking Alpha’s Quant systemMay 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market FearBy Jeffrey Neal Johnson | May 20, 2026MNPR, MSTR, and SEZL Company DescriptionsMonopar Therapeutics NASDAQ:MNPR$65.04 +0.61 (+0.95%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$65.00 -0.05 (-0.07%) As of 05/29/2026 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Strategy NASDAQ:MSTR$159.09 +7.45 (+4.91%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$158.97 -0.12 (-0.07%) As of 05/29/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Strategy Incorporated, formerly known as MicroStrategy, provides artificial intelligence-powered enterprise analytics software and services in the United States, Europe, the Middle East, Africa, and internationally. It offers Strategy ONE, a platform that allows non-technical users to access novel and actionable insights for decision-making, and Strategy Cloud for Government, which provides always-on threat monitoring designed to meet the strict technical and regulatory standards of governments and financial institutions. The company also delivers Strategy Support, helping customers achieve system availability and usage goals through responsive troubleshooting; Strategy Consulting, offering architecture and implementation services; and Strategy Education, which includes free and paid learning options. In addition, the company is actively involved in Bitcoin development. The company offers its services through direct sales force and channel partners. It serves the U.S. government, state and local governments, and government agencies, as well as a range of industries, including retail, banking, technology, manufacturing, insurance, consulting, healthcare, telecommunications, and the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.Sezzle NASDAQ:SEZL$118.15 -0.85 (-0.71%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$119.56 +1.41 (+1.19%) As of 05/29/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sezzle Inc. operates as a technology-enabled payments company primarily in the United States and Canada. The company provides payment solution in-store and at online retail stores; and through proprietary payments solution that connects consumers with merchants. It also offers Sezzle Platform that provides a payments solution for consumers that extends credit at the point-of-sale allowing consumers to purchase and receive the ordered merchandise at the time of sale while paying in installments over time; Pay-in-Four, which allows consumers to pay a fourth of the purchase price up front and then another fourth of the purchase price every two weeks thereafter over a total of six weeks; Pay-in-Full that allows consumers to pay for the full value of their order up-front through the Sezzle Platform without the extension of credit; and Pay-in-Two and other alternative installment options, which allow consumer to pay half of the value of their order up-front and the second half in two weeks. In addition, the company provides Sezzle Virtual Card that allows consumers to access the Sezzle Platform in the form of close-end installment loans and shop with merchants that are not integrated with Sezzle; Sezzle Anywhere, a paid subscription service that allows consumers to use their Sezzle Virtual Card at any merchant online or in-store; Sezzle Premium, a paid subscription service that allows its consumers to access large, non-integrated premium merchants; and Sezzle Up, an opt-in feature of the Sezzle Platform. Further, it offers Long-Term Lending through collaboration with third-party lenders and Product Innovation. Sezzle Inc. was incorporated in 2016 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
